Replies to post #91050 on Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

Think you may want to recheck the timeline and dosing level of the 10%. That was very early on in much earlier cohorts. Obtaining data from Dana Farber was pretty much cut off after that. Other than what was recently released of course.

Research conducted by the hospital evaluating p21 expression in earlier cohorts, for which the level of exposure to Kevetrin was substantially lower, showed that about 50 percent of the patients demonstrated at least a 10% increase in p21.

Message in reply to:

Having read a bit more a big question is whether increasing the MTD will in fact increase p21 levels. The company clearly sees this as a measure of success, and the initial info- 50% of patients with a 10% increase-is not great.

Knowing the next set of numbers is critical- if the trend is for increasing p21 with increasing MTD, as expected, calling it good news would be an understatement.

Look: coming across a stock OTC that might have a startling new drug for many types of cancer AND a number of revolutionary antibiotics, it seems too good to be true, really. And yet the more I read CTIX appears to be the real deal. Time will tell.

Sam.

[frrol]

I liken it to stumbling onto the "B" round of VC financing for a future Merck (slight exaggeration; CTIX mgmt doesn't want to be a Big Pharma), but on a public exchange.

The risks are there but the potential is enormous.